AI-driven cervical cancer screening device achieved FY25 sales of NZ$1.7m, with China as the dominant market. FY26 sales are forecast to exceed NZ$2.8m, driven by new public screening programs, expanded distribution, and a strategic alliance with Dalton Bio for HPV DNA tests.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.